Cell Cycle Proliferation and Epithelial-Mesenchymal Transition Pathway Scores Predictive of Recurrence and Survival for ccRCC
Research from the 2021 International Kidney Cancer Symposium North America identified prognostic value in cell cycle proliferation and epithelial-mesenchymal transition pathway scores in clear cell renal cell carcinoma in predicting survival and recurrence.
Cell cycle proliferation (CCP) and epithelial-mesenchymal transition (EMT) pathway scores were found to significantly identify patients who were going to develop disease recurrence and die from clear cell renal cell carcinoma (ccRCC), according to results from a poster presented at the 2021 International Kidney Cancer Symposium: North America.
Over-expression of Wilms tumor 1 (WT1) and CCP genes were observed in the discovery cohort in paired tumor thrombus compared with the primary tumor, and among patients with recurrence versus those without recurrence. The enrichment of EMT- and CCP-related pathways was observed among patients with a high WT1 expression in the TCGA validation ccRCC cohort, according to findings from a hallmark pathway analysis. Using the validation cohort CCP and EMT scores, investigators were able to stratify patients into 4 risk groups utilizing Youden-Index cut points. The groups included CCPlow/EMTlow, CCPhigh/EMTlow, CCPlow/EMThigh, and CCPhigh/EMThigh.
“We demonstrate the synergistic prognostic impact of EMT in tumors with high CCP score. Our novel EMT score has the potential to improve risk stratification and provide potential novel therapeutic targets,” the investigators wrote.
Patients with ccRCC were retrospectively analyzed in 2 cohorts, including those who underwent a radical nephrectomy (RNx) with inferior vena cava (IVC) tumor thrombectomy (n = 5) and those who underwent RNx for localized disease and developed recurrence compared with no recurrence (n = 36). The research team utilized samples from The Cancer Genome Atlas (TCGA) Research Network ccRCC cohort to validate results (n = 386). Kaplan-Meier and multivariable cox-proportional hazard testing were implemented to analyze the prognostic ability of CCP and EMT pathway scores on patient progression-free survival (PFS) and disease-specific survival (DSS).
Investigators identified an association between the CCPhigh/EMThigh risk group and the worst PFS (P < .001) and DSS (P < .001) outcomes. The group was also independently associated with poor PFS (HR, 4.6) and DSS (HR, 10.3; P < .001) outcomes, according to a multivariable analysis.
Other findings from a differential expression and pathway analysis of TCGA high and low WT1 tumors identified that the EMT pathway could be the top enriched pathway for those with high WT1 tumors.
“There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell carcinoma,” the investigators wrote in their poster. “Our novel EMT score has the potential to improve risk stratification and provide potential novel therapeutic targets.”
Reference
Nallandhighal S, Vince R, Karim R, et al. Molecular dissection of clear cell renal cell carcinoma reveals prognostic significance of epithelial-mesenchymal transition gene expression signature. Presented at 2021 International Kidney Cancer Symposium North America; November 5-6, 2021. Abstract LBA47
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
